Ovulation and pregnancy tests kits.
Medical devices : human and veterinary diagnostic rapid diagnostic kits.
Antigen rapid test kits.
Rapid antigen test kits..
Medical test kits like hirikon hiv 1/2 saliva home test kits.
Rapid test kit, hiv, hbsag, hcv, malaria, dengue, typhoid.
Rapid Diagnostics Test Kit.
Core diagnostic & rapid test kits and molecular kits..Manufacturer
Diagnostic test kits.
Diagnostic Kits Rapid Test Kits .
Rapid Test Kits Diagnostic Kits .
Diagnostic Kits Rapid Test Kits .
Antigen antibody rapid test kits.
Medical rapid test kits.
Anti-SARS-CoV-2 Rapid Test, COVID-19 1. Easier: No special equipment needed, Intuitive visual interpretation. 2. Rapid: Quick sampling by fingertip blood, Results in 10-15min. 3. Accurate: Results with IgG and IgM respectively. 4. Application: as screening tool for potential suspect patients in large numbers. Testing kit is FDA Emergency Use Authorization (EUA) Approved Testing kit is CE MARKED-IVD * Instruction for Use * Interpretation Guide * SARS-CoV-2 immunoassays * Accuracy of the Anti-SARS-CoV-2 Rapid Test Kit * Anti-SARS Rapid Test Brochure * COVID-19 Catalog * EUA Approval Letter * Fact Sheet for Healthcare Providers * FDA Letter * Fact Sheet for Recipients * FAQ * CE IVD Notification Certificate Antibody Performance Measure Estimate of Performance 95% Confidence Interval IgM Sensitivity (PPA) 95.7% (289/302) (92.8%; 97.5%) IgM Specificity (NPA) 99.7% (311/312) (98.2%; 99.9%) IgG Sensitivity (PPA) 99.0% (299/302) (97.1%; 99.7%) IgG Specificity (NPA) 99.4% (310/312) (97.7%; 99.8%) Combined Sensitivity (PPA) 99.0% (299/302) (97.1%; 99.7%) Combined Specificity (NPA) 99% (309/312) (97.2%; 99.7%) Combined PPV at prevalence = 5% 84.4% (64.6%; 94.6%) Combined NPV at prevalence = 5% 99.9% (99.8%; 100%) Testing kit is FDA Emergency Use Authorization (EUA) Approved Testing kit is CE MARKED-IVD * Instruction for Use * Interpretation Guide * SARS-CoV-2 immunoassays * Accuracy of the Anti-SARS-CoV-2 Rapid Test Kit * Anti-SARS Rapid Test Brochure * COVID-19 Catalog * EUA Approval Letter * Fact Sheet for Healthcare Providers * FDA Letter * Fact Sheet for Recipients * FAQ * CE IVD Notification Certificate
Product Details: Number of Reactions(Preps)/Kit :30T Brand : SD Biosensor ICMR Approved : Yes Result Time (Rapid Kits) : 10 min CAT No : RK019-30 STANDARD Q HIV 1/2 Ab 3-Line performs qualitative analysis by detecting antibodies specific to HIV-1 (including Group O) and HIV-2 in serum, plasma and whole blood using immunochromatography. With a simple test method, HIV infection status can be discriminated, and with its high sensitivity and specificity, the screening test result can be obtained within 10 minutes. Easy to use, Easy to read and interpret Discrimination between HIV-1 and HIV-2 antibodies Room temperature storage Performance Sensitivity : 100% (74/74)/ Specificity : 100% (232/232)
A rapid in vitro qualitative immunoassay for detection of antibodies to the Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) Clear, dependable results in 15 minutes Requires minimal training and no equipment So easy it can be used at the lowest levels of health care service Can use whole blood or serum/plasma Collection can be by fingerstick or venipuncture No refrigeration required Storage conditions 2-30�°C
COVID-19 Ag Rapid Test Device is an in vitro diagnostic rapidtest for the qualitative detection of antigen (Ag) in humannasopharyngeal swab specimens from individuals who meet COVID-19clinical and / or epidemiological criteria. COVID-19 Ag RapidTest Device is for professional use only and is intended to be used asan aid in the diagnosis of
COVID-19 serology test.Cellex qSARS-CoV-2 IgG/IgM Rapid Test.qSARS-CoV-2 IgG/IgM Rapid Test Cassette.FDA Grants Emergency Authorization for First Rapid Antibody Test for COVID-19
CAT No : RCHM-02071. The CareStar COVID-19 Antigen test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within first five days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.
